Get ready for 2025—ASF Walks are growing, and Angelman Strong is here! We’re thrilled to announce our new initiative where YOU can host or join a walk, 5K, or community event. We believe we can make an even bigger impact on the AS community. This is more than just an event—it’s a movement, a mission to raise awareness for Angelman syndrome and fund critical research and family support programs.
ASF funded research advance our understanding of AS and increase the potential for treatment & therapeutics.
FIND OUT MORE
Since her diagnosis, we have relied on the Angelman Syndrome Foundation as a source of information and support.
The Angelman Syndrome Clinic at MGH is a blessing for my adult child. Now we have somebody who really understands our needs.
Amazing things have happened because of the ASF-funded LGIT study from Boston’s MassGeneral Hospital. It was the beginning of a new era for treatments for our children with AS.
Latest press releases, articles and announcements
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). Highlights: Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement from […]
Read more
Ionis Pharmaceuticals issued a press release today regarding their Phase 1/2a HALOS clinical trial of ION582 for individuals living with Angelman syndrome. Read the Ionis press release here. Livestream Update on July 24 Join the livestream on July 24th at […]
Read more
Today, Ultragenyx Pharmaceuticals shared a press release announcing a “Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program.” Read the full press release. Livestream Update on Wednesday, July 24 Tune into the LIVESTREAM updates at the ASF Family Conference on […]
Read more
Ben Philpot, PhD and his lab at UNC Chapel Hill have identified a small molecule that could be a potential gene therapy treatment for AS. The ASF first funded Dr. Philpot’s pilot study to partner with Pfizer to evaluate over […]
Read more
